<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01149330</url>
  </required_header>
  <id_info>
    <org_study_id>BR.10.001</org_study_id>
    <nct_id>NCT01149330</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Safety of Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris</brief_title>
  <acronym>Estudo Epiduo</acronym>
  <official_title>Evaluation of Efficacy and Safety of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma Brasil Ltda.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma Brasil Ltda.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the efficacy of Adapalene 0.1%/Benzoyl Peroxide
      2.5% Gel in the treatment of acne vulgaris. The safety will also be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy evaluation</measure>
    <time_frame>Week 12</time_frame>
    <description>Changing from Baseline in Total Lesion count (Non-Inflammatory and Inflammatory lesions) in Week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary efficacy evaluation</measure>
    <time_frame>Week 1</time_frame>
    <description>Changing from Baseline in Total Lesion count (Non-Inflammatory and Inflammatory lesions) in Week 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary efficacy evaluation</measure>
    <time_frame>Week 2</time_frame>
    <description>Changing from Baseline in Total Lesion count (Non-Inflammatory and Inflammatory lesions) in Week 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changing from Baseline in Total Lesion count (Non-Inflammatory and Inflammatory lesions) in Week 2. Secondary efficacy evaluation</measure>
    <time_frame>Week 4</time_frame>
    <description>Changing from Baseline in Total Lesion count (Non-Inflammatory and Inflammatory lesions) in Week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary efficacy evaluation</measure>
    <time_frame>Week 8</time_frame>
    <description>Changing from Baseline in Total Lesion count (Non-Inflammatory and Inflammatory lesions) in Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary efficacy evaluation</measure>
    <time_frame>Week 12</time_frame>
    <description>Changing from Baseline in Total Lesion count (Non-Inflammatory and Inflammatory lesions) in Week 12.
Assessment of the severity of facial acne. Evaluation of global improvement at study completion. Assessment of improvement and patient satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation</measure>
    <time_frame>Week 1</time_frame>
    <description>Local tolerability scores - Erythema, Scaling, Dryness, Stinging/Burning at each study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation</measure>
    <time_frame>Week 2</time_frame>
    <description>Local tolerability scores - Erythema, Scaling, Dryness, Stinging/Burning at each study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation</measure>
    <time_frame>Week 4</time_frame>
    <description>Local tolerability scores - Erythema, Scaling, Dryness, Stinging/Burning at each study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation</measure>
    <time_frame>week 8</time_frame>
    <description>Local tolerability scores - Erythema, Scaling, Dryness, Stinging/Burning at each study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation</measure>
    <time_frame>Week 12</time_frame>
    <description>Local tolerability scores - Erythema, Scaling, Dryness, Stinging/Burning at each study visit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Adapalene-BPO Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene-BPO Gel</intervention_name>
    <description>Apply 1 gram of the investigational drug every night on whole face.</description>
    <arm_group_label>Adapalene-BPO Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female Subjects, aged 12 to 35 years inclusive, with moderate to severe facial
             acne vulgaris (described scale score of 3 or 4),

          -  Subjects with a minimum of 20 and a maximum of 50 Inflammatory Lesions (papules and
             pustules) on the face, excluding the nose,

          -  Subjects with a minimum of 30 and a maximum of 100 Non-Inflammatory Lesions (open
             comedones and closed comedones) on the face, excluding the nose,

          -  Female Subjects of childbearing potential with a negative urine pregnancy test at the
             Baseline visit and must practice a highly effective method of contraception during the
             study: oral/systemic [injectable, patchâ€¦] contraception (must have been on a stable
             dose for 3 months prior to study entry), Intrauterine Device, strict abstinence,
             condoms, diaphragms, sponge, spermicides or partner had a vasectomy,

          -  Females of non-childbearing potential, i.e., premenses, post-menopausal (absence of
             menstrual bleeding for 2 years), hysterectomy, bilateral tubal ligation, or bilateral
             ovariectomy, secondary infertility and sterility are not required to have a UPT at the
             beginning of the study,

          -  Subjects have to read and sign the approved the Informed Consent form prior to any
             participation in the study. Subjects under the majority must sign an
             assent-to-participate form to participate in the study and they must have one parent
             or guardian read and sign the Informed Consent form prior to any study related
             procedure,

          -  Subjects willing and capable of cooperating to the extend and degree required by the
             protocol.

        Exclusion Criteria:

          -  Subjects who have participated in another investigational drug or device research
             study within 30 days of enrollment,

          -  Female Subjects who are pregnant, nursing or planning a pregnancy during the study,

          -  Subjects with more than 1 nodule or cyst on the face

          -  Subjects with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced
             acne, etc.),

          -  Subjects with known or suspected allergy to one of the investigational products (see
             package insert and/or investigator brochure),

          -  Subjects who have pathological conditions photosensitive porphyria, SLE, LED, solar
             polymorphous eruption, actinic prurigo, solar urticaria, etc.

          -  Subjects with a beard or other facial hair that might interfere with study
             assessments,

          -  Subjects who foresee intensive UV exposure during the study (mountain sports, UV
             radiation, sunbathing, etc...)

          -  Female subjects with a history of hormonal changes.

          -  Subjects with skin condition or disease requiring topical or systemic therapy, which
             interferes with the investigational product or that may directly affect the evaluation
             criteria:

               -  Topical treatment for acne in the past two weeks.

               -  Anti-inflammatory topic in the last two weeks.

               -  Use of topical corticosteroids on the face in the last four weeks.

               -  Anti-inflammatory systemic (hormonal or not) in the last four weeks.

               -  Use of systemic corticosteroids in the last four weeks.

               -  Systemic antibiotics in the last four weeks (excluding penicillins).

               -  Systemic retinoids in the last six months.

               -  Other systemic anti-acne the last four weeks.

               -  Anticonceptional oral used exclusively for the control of acne in the past six
                  months.

               -  Cosmetic procedures such as facials, peels, exfoliation, extraction of comedones,
                  application of LED, laser or pulsed light in the last two weeks.

               -  Cosmetic procedures such as PDT in the last four weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandra T Nogueira, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galderma Brasil Ltda.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ServiÃ§o de Dermatologia do AmbulatÃ³rio MagalhÃ£es Neto do Complexo HUPES - Universidade Federal da Bahia</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>40110-160</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituo da Pele</name>
      <address>
        <city>Goiania</city>
        <state>Goias</state>
        <zip>74125-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital De ClÃ­nicas - Universidade Federal do ParanÃ¡</name>
      <address>
        <city>Curitiba</city>
        <state>ParanÃ¡</state>
        <zip>80060-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KOLderma Instituto de Pesquisa ClÃ­nica Ltda</name>
      <address>
        <city>Campinas</city>
        <state>Sao Paulo</state>
        <zip>13020-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Dermatologia e EstÃ©tica do Brasil Ltda.</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22470-220</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de AssistÃªncia MÃ©dica ao Servidor PÃºblico Estadual</name>
      <address>
        <city>Sao Paulo</city>
        <zip>02404-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2010</study_first_submitted>
  <study_first_submitted_qc>June 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2010</study_first_posted>
  <last_update_submitted>March 9, 2012</last_update_submitted>
  <last_update_submitted_qc>March 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2012</last_update_posted>
  <responsible_party>
    <name_title>Alessandra Nogueira, MD</name_title>
    <organization>Galderma Brasil Ltda.</organization>
  </responsible_party>
  <keyword>Adapalene</keyword>
  <keyword>Benzoyl Peroxide</keyword>
  <keyword>Acne Vulgaris</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzoyl Peroxide</mesh_term>
    <mesh_term>Adapalene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

